Nuwellis Welcomes University of Iowa Health Care Stead Family Children’s Hospital as Newest Pediatric Customer
Nuwellis announces that University of Iowa Health Care Stead Family Children's Hospital has adopted the Aquadex SmartFlow® system for treating pediatric patients with fluid overload due to heart and kidney disease. The system provides adjustable ultrafiltration therapy for critically ill children experiencing excess fluid buildup. Dr. Kyle Merrill, Associate Medical Director of Pediatric Dialysis, highlights that fluid overload increases ICU time, ventilator dependency, and mortality rates. The hospital previously relied on diuretics and conventional dialysis methods. The Aquadex therapy offers a new solution for managing fluid overload in their most critical pediatric patients, aiming to improve outcomes and quality of life.
Nuwellis annuncia che l'ospedale pediatrico Stead Family dell'Università dell'Iowa ha adottato il system Aquadex SmartFlow® per il trattamento dei pazienti pediatrici con sovraccarico di fluidi a causa di malattie cardiache e renali. Questo sistema fornisce una terapia di ultrafiltrazione regolabile per i bambini gravemente malati che sperimentano un accumulo eccessivo di liquidi. Il Dr. Kyle Merrill, Direttore Medico Associato della Dialisi Pediatrica, sottolinea che il sovraccarico di fluidi aumenta il tempo in terapia intensiva, la dipendenza dai ventilatori e i tassi di mortalità. L'ospedale in precedenza si affidava a diuretici e metodi di dialisi convenzionali. La terapia Aquadex offre una nuova soluzione per gestire il sovraccarico di fluidi nei loro pazienti pediatrici più critici, con l'obiettivo di migliorare i risultati e la qualità della vita.
Nuwellis anuncia que el Hospital Infantil Stead Family de la Universidad de Iowa ha adoptado el sistema Aquadex SmartFlow® para tratar a los pacientes pediátricos con sobrecarga de líquidos debido a enfermedades cardíacas y renales. Este sistema proporciona terapia de ultrafiltración ajustable para niños gravemente enfermos que experimentan acumulación excesiva de líquidos. El Dr. Kyle Merrill, Director Médico Asociado de Diálisis Pediátrica, destaca que la sobrecarga de líquidos incrementa el tiempo en la UCI, la dependencia del ventilador y las tasas de mortalidad. El hospital solía depender de diuréticos y métodos de diálisis convencionales. La terapia Aquadex ofrece una nueva solución para gestionar la sobrecarga de líquidos en sus pacientes pediátricos más críticos, con el objetivo de mejorar los resultados y la calidad de vida.
Nuwellis는 아이오와 대학교 스티드 패밀리 아동 병원이 심장 및 신장 질환으로 인한 체액 과다 치료를 위해 Aquadex SmartFlow® 시스템을 도입했다고 발표했습니다. 이 시스템은 과도한 체액 축적을 겪고 있는 중증 아동을 위한 조정 가능한 초여과 요법을 제공합니다. 소아 투석의 부의 의사인 Kyle Merrill 박사는 체액 과다가 중환자실 체류 시간, 인공호흡기 의존도 및 사망률을 증가시킨다고 강조합니다. 병원은 이전에 이뇨제와 기존의 투석 방법에 의존했습니다. Aquadex 요법은 가장 위급한 소아 환자의 체액 과다 관리를 위한 새로운 해결책을 제공하며, 결과와 삶의 질을 개선하는 것을 목표로 하고 있습니다.
Nuwellis annonce que l'hôpital pédiatrique Stead Family de l'université de l'Iowa a adopté le système Aquadex SmartFlow® pour traiter les patients pédiatriques souffrant d'une surcharge liquidienne due à des maladies cardiaques et rénales. Ce système fournit une thérapie d'ultrafiltration ajustable pour les enfants gravement malades rencontrant une accumulation excessive de liquides. Le Dr Kyle Merrill, directeur médical adjoint de la dialyse pédiatrique, souligne que la surcharge liquidienne augmente le temps en soins intensifs, la dépendance aux ventilateurs et les taux de mortalité. L'hôpital comptait auparavant sur des diurétiques et des méthodes de dialyse conventionnelles. La thérapie Aquadex offre une nouvelle solution pour gérer la surcharge liquidienne de leurs patients pédiatriques les plus critiques, visant à améliorer les résultats et la qualité de vie.
Nuwellis gibt bekannt, dass das Stead Family Kinderkrankenhaus der Universität von Iowa das Aquadex SmartFlow®-System zur Behandlung von pädiatrischen Patienten mit Flüssigkeitsüberlastung aufgrund von Herz- und Nierenerkrankungen übernommen hat. Das System bietet eine anpassbare Ultrafiltrations-Therapie für schwerkranke Kinder, die unter übermäßigem Flüssigkeitsaufbau leiden. Dr. Kyle Merrill, stellvertretender medizinischer Direktor der pädiatrischen Dialyse, hebt hervor, dass Flüssigkeitsüberlastung die Verweildauer auf der Intensivstation, die Abhängigkeit von Beatmungsgeräten und die Sterblichkeitsraten erhöht. Das Krankenhaus hatte zuvor auf Diuretika und herkömmliche Dialyse-Methoden gesetzt. Die Aquadex-Therapie bietet eine neue Lösung zur Bewältigung der Flüssigkeitsüberlastung bei den kritischsten pädiatrischen Patienten und zielt darauf ab, die Ergebnisse und die Lebensqualität zu verbessern.
- New customer acquisition in pediatric segment
- Expansion of market presence in healthcare institutions
- Strategic growth in pediatric business segment
- None.
Insights
The adoption of the Aquadex SmartFlow system by University of Iowa Health Care Stead Family Children's Hospital represents a significant business opportunity for Nuwellis in the pediatric care market. The system addresses a critical medical need for precise fluid management in critically ill children with heart and kidney diseases.
The technology's key advantages include:
- More precise fluid removal compared to conventional dialysis
- Potential reduction in ICU stays and ventilator time
- Alternative to traditional diuretics and dialysis treatments
For investors, this partnership with a major children's hospital could serve as a reference site to drive adoption at other pediatric centers. However, with Nuwellis's small market cap of
MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that University of Iowa Health Care Stead Family Children’s Hospital in Iowa City, Iowa, has adopted the Aquadex SmartFlow® system to treat pediatric patients suffering from fluid overload due to heart and kidney disease.
The Stead Family Children’s Hospital will use the Aquadex SmartFlow system to provide adjustable ultrafiltration therapy for critically ill children experiencing excess fluid buildup. This therapy will allow for safe and effective fluid removal, which is critical in managing severe heart and kidney conditions.
Kyle Merrill, MD, MS, Associate Medical Director of Pediatric Dialysis and Director of Acute/Inpatient Dialysis, the physician leading the implementation of Aquadex SmartFlow at Stead Family Children’s Hospital, expressed his enthusiasm for the new treatment option. “Several of our patients experience fluid overload due to both heart disease and kidney disease. Significant fluid overload if left untreated increases time in the ICU, time on the ventilator and overall hospital length of stay as well as mortality of our patients. Previously, we relied on medical management including diuretics or medications to improve urine output or conventional dialysis modalities like hemodialysis or continuous renal replacement therapy to remove excess fluid. We are excited to have access to Aquadex therapy, which offers a new and innovative way to manage fluid overload in our sickest pediatric patients. Having this advanced option means we can better support children with heart and kidney disease, improve their outcomes, and provide them with a better quality of life.”
Nuwellis’ President and CEO, Nestor Jaramillo, also commented on the partnership. “We are thrilled to partner with University of Iowa Health Care Stead Family Children’s Hospital, Dr. Merrill, and his team to be part of their mission to provide world-class care to children. This collaboration reflects our commitment to expanding access to life-saving fluid management solutions for hospitals across the country and growing our pediatric business. By working together, we are helping more patients receive the care they need when it matters most.”
The Aquadex SmartFlow system is designed to safely remove excess fluid in patients suffering from fluid overload, a condition that often accompanies heart failure, kidney disease, and other critical conditions. This system is an important tool in pediatric care, where precise fluid management is crucial to improving patient outcomes.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2024 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
CONTACTS
Investors:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com
FAQ
What is the new pediatric customer for Nuwellis (NUWE) announced in October 2023?
What medical conditions will the Aquadex SmartFlow system treat at Stead Family Children's Hospital?
How does fluid overload affect pediatric patients according to Dr. Merrill?
